KARD Kardigan (KARD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0002123613
Cluster · 3 insidersActivist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
69
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · no price filed
What the filings say about KARD
Insiders, 180 days
+$90.0M net bought
3 buyers
Activist stakes (13D), 180 days
2 filings
Largest: 16.2% of the class
Kardigan insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Kardigan, Inc. insiders bought a net $90.0M of stock across 3 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 21.0% of the 14,866,868 shares held after it.
- 2 other insiders bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HRTG PV, L.P. bought about $50.0M of KARD on Jun 22, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 69 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.3% of the 15,042,035 shares held after it.
- 2 other insiders bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BERNS PAUL L bought about $20.0M of KARD on Jun 22, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 69 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.3% of the 15,042,035 shares held after it.
- 2 other insiders bought within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NELSEN ROBERT bought about $20.0M of KARD on Jun 22, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 69 funds added in the latest 13F quarter.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$90.0M over 180 days
+$90.0M of it by a 10%+ holder
more than 99% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
69 funds bought in last quarter
more than 56% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
8.6% of the float short (float per yahoo 2026-10-26) · 3.8 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
The situation: each line is one rule over one dataset
ARCH Venture Fund XIII, L.P. disclosed a 5%+ stake (16.2%) in the last six months.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch KARD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-41.8%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns KARD: institutional holders (13F)
13F holdings, latest reported quarter
16,917,034 sh
$403.5M
8,909,066 sh
$212.5M
8,200,662 sh
$195.6M
3,598,942 sh
$85.8M
1,790,734 sh
$46.4M
Congress trades in KARD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
ARCH Venture Fund XIII, L.P.
Activist 13D · 2026-06-29
16.2%
ARCH Venture Partners XIII, L.P.
Activist 13D · 2026-06-29
16.2%
ARCH Venture Partners XIII, LLC
Activist 13D · 2026-06-29
16.2%
Robert Nelsen
Activist 13D · 2026-06-29
16.2%
Keith Crandell
Activist 13D · 2026-06-29
16.2%
KARD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
KARD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
JPMorgan Small Cap Growth Fund
$19.6M position · as of 2026-06-30
0.8%
AB Small Cap Growth Portfolio
$338.2K position · as of 2026-06-30
0.6%
AB Small Cap Growth Portfolio
$17.7M position · as of 2026-06-30
0.6%
MFS New Discovery Series
$4.2M position · as of 2026-06-30
0.5%
BNY Mellon Small/Mid Cap Growth Fund
$4.3M position · as of 2026-06-30
0.5%
Carillon Chartwell Small Cap Growth Fund
$801.5K position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
1 active
1
Phase 3
1 active
2
Multi-phase
2 active
What changed recently
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Ge
2026-09-03 · Not Yet Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $90.0M bought by insiders over 180 days, 69 funds added last quarter. Each figure is a federal filing, dated the day it went public.
KARD Stock Sonar score 3/7 axes
Find similar shapesCompareKARD ranks highest on insider conviction (94th percentile) and institutional and government (56th), and lowest on risk and compliance (44th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
KARD filings, in plain words
Are Kardigan insiders buying or selling KARD?
In the 180 days to 2026-10-27, Kardigan insiders were net buyers, a net $90.0M across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-27, Kardigan insiders were net buyers of KARD, a net $90.0M across purchases and sales reported on Form 4 by 3 buyers. Most of that figure, $90.0M, came from a holder of 10% or more rather than an officer or director. 3 insiders reported purchases in that window. 2 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 16.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
